Design Therapeutics Inc (DSGN)
3.29
-0.06
(-1.79%)
USD |
NASDAQ |
Jun 26, 10:38
Design Therapeutics Free Cash Flow (Quarterly): -12.63M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -12.63M |
December 31, 2023 | -12.82M |
September 30, 2023 | -14.59M |
June 30, 2023 | -13.89M |
March 31, 2023 | -17.51M |
December 31, 2022 | -15.38M |
September 30, 2022 | -14.21M |
June 30, 2022 | -10.74M |
March 31, 2022 | -11.90M |
Date | Value |
---|---|
December 31, 2021 | -9.581M |
September 30, 2021 | -9.132M |
June 30, 2021 | -8.472M |
March 31, 2021 | -3.73M |
December 31, 2020 | -2.858M |
September 30, 2020 | -1.921M |
June 30, 2020 | -1.307M |
March 31, 2020 | -2.659M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-17.51M
Minimum
Mar 2023
-1.307M
Maximum
Jun 2020
-9.608M
Average
-10.74M
Median
Jun 2022
Free Cash Flow (Quarterly) Benchmarks
Biogen Inc | 432.30M |
AbbVie Inc | 3.847B |
PTC Therapeutics Inc | 6.41M |
Revance Therapeutics Inc | -71.11M |
Context Therapeutics Inc | -4.361M |